Schrödinger (SDGR) Jefferies Global Healthcare Conference 2025 summary

Executive introductions and business focus

• New CFO brings M&A and healthcare experience, focusing on software growth and predictive toxicology initiatives.

• CMO oversees three proprietary phase I agents in the clinic, with extensive drug development background.

• President of R&D also leads strategy for partnering, emphasizing platform and collaboration.

Platform overview and monetization

• Digital chemistry lab platform combines physics-based methods with AI/ML for molecular discovery.

• Monetization includes software sales, proprietary pipeline, and pharma partnerships with milestones and royalties.

• Eight disclosed pipeline assets, three in phase I oncology, with ongoing updates planned.

Financial performance and guidance

• Q1 revenue reached $59.6M, with software revenue up 46% year-on-year.

• Ended Q1 with $512M in cash, including $150M from a Novartis deal.

• 2024 guidance: 10%-15% revenue growth, $45M-$50M drug discovery revenue, <5% OpEx growth, Q2 revenue estimate $38M-$42M.